VBI Vaccines will attend the Boston Oppenheimer Summit Oncology Insight 2018

CAMBRIDGE, Mbad., July 9, 2018 (GLOBE NEWSWIRE) – VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial biopharmaceutical company developing next-generation vaccines against infectious and immuno-oncological diseases , announced today that the company will attend the Oppenheimer Boston Oncology Summit Insight Summit from July 10-11, 2018. The two-day summit will include a series of discussions with researchers from the Whitehead Institute at Cambridge, Mbadachusetts, followed by an appointment with institutional investors at the Four Seasons Hotel in Boston, Mbadachusetts.

To learn more about the event, visit the following link:
https://www.opco.com/conferences/oncology18/index.aspx .

About VBI Vaccines Inc. [19659004] VBI Vaccines Inc. ("VBI") is a commercial biopharmaceutical company developing a new generation of vaccines to address unmet needs in infectious diseases and diseases. 39; immuno-oncology. The first product marketed by VBI is Sci-B-Vac ^® a vaccine against hepatitis B (HBV) that mimics the three viral surface antigens of the hepatitis B virus; Sci-B-Vac ^® is approved for use in Israel and 14 other countries. VBI's eVLP Platform technology enables the development of enveloped virus-like virus (eVLP) vaccines that closely mimic the target virus to induce a potent immune response. VBI is advancing an eVLP vaccine pipeline, with lead programs in cytomegalovirus (CMV) and glioblastoma (GBM). VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel